Open access peer-reviewed chapter

Malignant Interaction between B Cells and T Helper Cells

Written By

Simone Bürgler

Submitted: 24 November 2016 Reviewed: 23 March 2017 Published: 12 July 2017

DOI: 10.5772/intechopen.68731

From the Edited Volume

Lymphocyte Updates - Cancer, Autoimmunity and Infection

Edited by Gheorghita Isvoranu

Chapter metrics overview

1,671 Chapter Downloads

View Full Metrics


Collaboration of T helper (Th) cells with B cells is central for the generation of high-affinity antibodies with distinct effector function and thus for the establishment of effective immune responses. Physiological T cell help for B cells takes place in germinal centers (GC) in peripheral lymphoid organs, where follicular T helper (Tfh) cells interact with mature, antigen-stimulated B cells. Occasionally, B cells undergo malignant transformation, which may lead to the development of leukemia or lymphoma. Over the past decades, it has become increasingly clear that cancer cells depend on interactions with the tumor microenvironment for growth and survival. Since many B cell malignancies develop in GC—the place of physiological Th cell-B cell interaction—Th cells are a central part of the tumor microenvironment of B cell leukemia and lymphoma. Thus, while the interaction between Th cells and normal B cells is crucial for the development of an effective immune response, this interaction also contributes to the development and pathogenesis of malignancies. The present chapter discusses the mechanisms underlying Th cell-mediated support of malignant B cells contributing to the pathogenesis of leukemia and lymphoma. Research efforts aiming to elucidate such mechanisms are of high importance as therapeutic targeting of these malignant interactions may increase treatment efficiency and reduce disease relapse.


  • T helper cells
  • B cells
  • leukemia
  • lymphoma
  • B cell malignancies
  • Th cell-B cell interaction
  • tumor microenvironment

1. Introduction

The human immune system is made up of two branches: the innate immune system consisting of dendritic cells, macrophages, granulocytes and natural killer (NK) cells mounts a fast but nonspecific response against invading pathogens. The adaptive immune system, in contrast, raises a delayed but highly specific response. In this response, T cells and B cells use their greatly diverse receptors—T cell receptors (TCRs) and B cell receptors (BCRs), respectively—to recognize antigenic epitopes of invading pathogens [1]. Antigenic stimulation of the receptors on the B cell’s and T cell’s surface induces intracellular signaling cascades that lead to the activation, proliferation and differentiation of the cell. The BCR is also synthesized in a soluble form and can be secreted by B cells as antibody, also known as immunoglobulin (Ig). Antibodies recognize pathogens and neutralize them by various mechanisms. In order to generate high-affinity antibodies with distinct effector functions, B cells need the help of T cells. Thus, the establishment of a specific and efficient immune response requires a close collaboration of T cells and B cells.

1.1. Physiological Th cell-B cell interaction

T cells arise in the bone marrow (BM) and mature in the thymus. Two T cell populations can be distinguished: the CD8+ T cytotoxic (Tc) cells and the CD4+ Th cells. Tc cells can kill infected cells through release of molecules like granzymes or perforin, while Th cells have the task to activate other immune cells and to instruct them to raise an appropriate immune response.

Naïve Th cells leave the thymus and migrate to the periphery, where they encounter antigenic peptides presented by antigen-presenting cells (APCs) such as macrophages, B cells and dendritic cells (DCs). APC secrete a distinct set of cytokines, the composition of which depends on the pathogen encountered. Upon stimulation, the activated Th cells rapidly divide and differentiate into one of several different effector subsets that are characterized by the expression of distinct transcription factors, surface markers and cytokines. This differentiation is governed by the cytokines that are secreted by the APC and the surrounding cells at the time point of naïve Th cell activation. Thereby, APC not only activates naïve Th cells but also tailors their properties according to the pathogens to be defeated.

The first Th cell subsets that have been described were Th1 cells, characterized by expression interferon (IFN)-γ, and Th2 cells, producing interleukin (IL)-4, IL-5 and IL-13 [2]. Later, further effector lineages such as Th17, Th9 or Th22 have been described. In addition, several Th cell subsets with regulatory or suppressive functions, so-called regulatory T (Treg) cells, exist [3].

Follicular helper T (Tfh) cells are a unique population of Th cells distinct from extrafollicular and peripheral Th cells. Tfh cells are characterized by the expression of the inducible T cell costimulator (ICOS) receptor, the chemokine receptor CXCR5, the programmed cell death-1 (PD-1) inhibitory receptor and the transcription factor BCL6 that controls their development and function [46].

B cells develop and mature in the BM and then migrate to the secondary lymphoid organs, where the antigen-dependent phase of their development takes place. While this process can be independent of T cell help, conventional B cells predominantly undergo T cell-dependent (TD) responses. Upon BCR stimulation by an antigen presented by follicular dendritic cells (FDCs), B cells migrate to the boundary between the follicle and the outer T cell zone, where they interact with Tfh cells [7]. Cognate interaction of B cells and Tfh cells involves internalization and presentation of an antigen via the BCR, ligation of CD40 on the B cell by its ligand CD40L on the Tfh cell, as well as the cytokines IL-4 and IL-21. B cells then develop either into short-lived plasma cells that secrete low-affinity antibodies or they differentiate into GC B cells that further give rise to long-lived memory B cells and plasma cells producing high-affinity antibodies. While memory B cells enter the circulation, plasma cells migrate and home to the BM.

The activating signals from Tfh cells induce upregulation of activation-induced cytidine deaminase (AID), a DNA-editing enzyme that initiates somatic hypermutation (SHM) and class-switch recombination (CSR) [8]. Introduction of point mutation by AID into the variable region of the IG genes during SHM leads to highly variable Ig proteins that build the base for high-affinity antibodies [9]. During CSR, the constant parts of IgM and IgD (Cμ and Cδ, respectively) are replaced by Cγ, Cα or Cε, giving rise to IgG, IgA or IgE. Thereby, CSR creates antibodies with diverse effector functions while retaining the antigen specificity [10]. B cells then differentiate into highly proliferating GC B cells called centroblasts before developing into centrocytes. As centrocytes, they screen antigens on the surface of FDC using their newly mutated BCR. High-affinity interaction with antigen results in survival and thus selection of centrocytes with high-affinity BCR, leading to recycling of centrocytes into centroblasts and to the differentiation of centrocytes into memory B cells and plasma cells.

During B cell development, however, B cells or their precursors occasionally undergo malignant transformation, which may result in the development of leukemia or lymphoma (Figure 1). Such transformations are frequently initiated by genetic events leading to aberrantly expressed proteins. Nevertheless, these chromosomal abnormalities alone are usually not sufficient for cancer development, and the transformed cells are not able to survive and outgrow when isolated and cultured in vitro. Thus, while mutations may trigger malignant transformation, interactions with the tumor microenvironment seem to be essential for the development and pathogenesis of most B cell malignancies.

Figure 1.

Schematic overview over the B cell development in the BM and GC with the most important developmental stages (black) and the B cell malignancies covered in this chapter (red). Red arrows indicate the presumed cell of origin of the malignant cells.


2. Main body

2.1. Malignant Th cell-B cell interaction

The tumor microenvironment plays a key role in supporting survival and expansion of cancer cells in virtually all known malignancies [1113]. Malignancies of B cell origin often arise from GC B cells. Consequently, the cells of the GC microenvironment represent key collaboration partners of cancer cells during pathogenesis, progression and relapse of leukemia and lymphoma. The supportive tumor microenvironment in GC is made up by nonhematopoetic as well as lymphoid cells such as mesenchymal stromal cells, fibroblasts, macrophages, FDC and Tfh cells, which build a complex network and mutually regulate their activation differentiation, migration and expansion. Thus, while cells of the microenvironment support the tumor cells, the tumor cells in turn support and shape the cells that surround them in a way that maximizes their own benefit.

Generally, malignantly transformed B cells seem to retain their ability to interact with Th cells, and thus remain capable of profiting from Th cell help. Hence, while the support of normal mature B cells by Th cells plays a central role in the generation of an adaptive immune response, the support of malignant B cells by Th cells may promote lymphoma or leukemia.

2.2. Malignant Th cell-B cell interaction: follicular lymphoma

Follicular lymphoma (FL) is the most frequent indolent lymphoma. The initial response rates to therapy are relatively high but relapses are frequent. The malignant cells express the GC B cell markers BCL6 and CD10 and display a gene expression profile of centrocytes [14]. FL cells are characterized by an overexpression of the antiapoptotic protein BCL2 caused by a t(14;18) translocation. Nevertheless, this genetic aberration is not sufficient for lymphoma development, and isolated primary FL cells fail to survive and proliferate in vitro, suggesting that the tumor microenvironment plays a major role in FL development and progression. Both nonhematopoietic cells as well as Th cells are crucially involved in FL cell growth and survival [15]. Tfh cells from FL-affected lymph nodes display a distinct gene expression profile that differs from normal tonsillar Tfh cells by an increased expression of IL2, IL4 and the proinflammatory cytokines IFN and TNF [16]. Consistently, high levels of IL-4 are associated with FL cell activation [17]. Similarly, support of FL cells by Th cells seems to be mediated by Tfh cell-derived CD40L and IL-4 [18]. The proinflammatory cytokines expressed by Tfh of FL patients, in contrast, seem to modulate the FL supportive environment rather than having a direct effect on FL cells. TNF, e.g., has been suggested to sustain differentiation and survival of the lymphoid stroma network in FL [19].

Besides cytokines, the membrane-bound molecule CD40L is important for Th cell-mediated FL cell support, since FL cells showed an increased survival when stimulated by CD40 crosslinking in vitro [20] as well as upon cognate interaction with Th cells [21], and it has been suggested that CD40L stimulation protects FL cells from TRAIL-mediated apoptosis in an NF-κB-dependent manner [22].

About 70% of FL patients display BM infiltration at diagnosis. Interestingly, the affected BM is characterized by an overrepresentation of Th cells [23]. This further supports the importance of Tfh cells in FL disease pathogenesis.

2.3. Malignant Th cell-B cell interaction: Burkitt’s lymphoma

Burkitt’s lymphoma (BL) is an aggressive B cell cancer, probably arising from GC B cells [24]. Three main subtypes of BL are currently identified epidemiologically, though histologically the tumors are indistinguishable. Endemic BL (eBL), the classical BL, is found in malaria-endemic regions, while sporadic BL (sBL) is relatively rare and most commonly found outside malaria-affected areas. HIV-associated BL is often described as separate subtype as well [25]. eBL is strongly associated with the Epstein-Barr Virus (EBV), even though the pathogenic mechanism is not clear [26, 27]. The role of Th cells in BL development and progression is highly controversial. Several studies showed that EBV-specific Th cells can kill BL cell lines or EBV-transformed B cells [2835] or limit their proliferation [36]. Most of these studies, however, used a nonphysiologically high effector to target ratio and thus require careful interpretation. Other researchers, in contrast, have reported that EBV-specific Th cells induced B cell proliferation [37], and in several mouse models EBV-specific Th cells were even required for lymphomagenesis [3840]. Finally, two studies found that virus and autoantigen-specific Th cells can both kill and support EBV-transformed B cells [41, 42], suggesting that the role of Th cells in BL and other EBV-associated malignancies is likely to be context dependent. Interestingly, the chance of BL development in HIV patients is associated with CD4+ T cell count, as the incident of BL development decreases with reduced CD4+ T cell numbers [43], supporting a BL-promoting role for Th cells.

2.4. Malignant Th cell-B cell interaction: Hodgkin lymphoma

In Hodgkin lymphoma (HL), the malignant B cells—called Reed-Sternberg (RS) cells—constitute only a minor fraction of the tumor. The remainder consists of eosinophils, fibroblasts, macrophages, plasma cells and Tc as well as Th cells. Infiltration of certain Th cell subsets has been correlated with reduced overall patient survival, even though the exact function of these infiltrating Th cells is not fully clear [44, 45]. Several cytokines seem to have a stimulatory effect on RS cells, one of which is the Th2 cytokine IL-13 [46]. Nevertheless, IL-13 can also be produced by RS cells themselves and act in an autocrine manner. Thus, a direct role of Th cells remains to be demonstrated. The complexity of the tumor microenvironment in HL, where a wide range of cells mutually influence each other, makes it intricate to discern the roles of the individual components.

2.5. Malignant Th cell-B cell interaction: chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is a malignancy of mature clonal CD5+ B cells, although the precise cell of origin is still debated [47]. CLL cells proliferate in pseudofollicles in secondary lymphoid organs and in the BM, where they receive support from cells of the stromal microenvironment [48]. CLL cells were found to interact with endothelial cells, stroma cells and monocyte-derived nurse-like cells, and to receive antiapoptotic signals via cytokines and chemokines. In addition, Th cells infiltrate such CLL pseudofollicles [49]. The infiltrating Th cells were shown to have an activated phenotype and to be actively recruited to these niches by CLL cells via chemokines [50]. Furthermore, they were able to activate CLL cells and to induce an upregulation of the surface molecule CD38, which is associated with poor prognosis [51].

We hypothesized that proliferation of CLL cells in patients was driven by a cognate interaction of Th cells with CLL cells, comparable to the physiological interaction between Th cells and GC B cells [52]. According to this hypothesis, CLL cells would present antigen to antigen-specific Th cells and in turn receive stimuli for their survival. Such an antigen could either be endogenous or it could be derived from an external pathogen. A key premise for this mechanism of CLL expansion in patients is the ability of resting CLL cells to efficiently activate Th cells. Thus, to study the antigen-presentation capacity of CLL cells, we used a human Th cell clone that is specific for a peptide derived from the mouse Ig kappa (Igκ) light chain [53], and human leukocyte antigen (HLA)-matched CLL cells from CLL patients, which allowed us to study antigen-dependent cognate interaction of CLL cells and Th cells (Figure 2). Using this model, we found that CLL cells were able to endocytose antigen through endocytic receptors such as the Fc receptors CD32 and CD23 and through their BCR. Furthermore, CLL cells were surprisingly potent stimulators of Th cell proliferation. With the exception of one patient, the function of CLL cells was comparable to that of normal B cells. Reciprocally, CLL cells were activated by antigen-activated Th cells. They upregulated the activation markers CD38 and CD69, and molecules involved in the interaction with Th cells such as HLA-DR, the costimulatory molecule CD86, the adhesion molecule CD54 and receptors for Th cell help such as CD40 and CD25. Surface expression of CD27 and CD275 (ICOS-ligand) was reduced, in line with activation-induced shedding. In addition, CLL cells proliferated upon interaction with Th cells, which was dependent on antigen and cell-cell contacts, as well as on CD40-CD40L interaction. Furthermore, the Th cell-stimulated CLL cells had a gene expression profile similar to CLL cells within CLL proliferation centers, suggesting that in vitro interactions with Th cells reflected interactions with the lymph node microenvironment in patients.

Figure 2.

Model system to assess the antigen-presentation capacity of CLL cells: HLA-DRB1*0401+ CLL cells are cocultured with a human Th cell clone (T18) that is specific for an epitope in mouse Igκ chain, when presented on HLA-DRB1*0401. Mouse Igκ+ antibodies against various surface molecules on the CLL cells such as CD23, CD32 or BCR are added. T18 cell proliferation is assessed as a read out for the capacity of CLL cells to endocytose and process these antibodies and to present Igκ peptides to the T18 cells together with provision of costimulatory signals.

While the results obtained using this model system demonstrated that CLL cells had the ability to activate Th cells and receive help for their survival and proliferation, it remained to be elucidated whether such interaction actually occurred in CLL patients. Indeed, we found that CLL patients harbored Th cells that proliferated in response to both autologous CLL cells as well as autologous CLL cell lysate presented by peripheral blood mononuclear cells (PBMCs) from HLA-matched donors. Similar to the results obtained using the model system, CLL-specific Th cells stimulated CLL cell activation and proliferation in an antigen- and CD40L-dependent manner. In in vivo xenograft experiments, the Th cell-induced CLL proliferation was even more pronounced, suggesting that stromal factors may act synergistically during the Th cell-CLL cell collaboration.

The remaining unresolved point was the identification of the antigenic source of the cognate interaction between Th cells and CLL cells. The hypervariable regions of the CLL cells’ BCR represent good candidate for endogenous antigens, since peptides derived from these regions are presented on major histocompatibility complex class II (MHCII), and are likely to be recognized as foreign by autologous Th cells.

To test this hypothesis, we used monoclonal antibodies derived from CLL cell hybridoma as source of antigen and HLA-matched donor PBMC as antigen-presenting cells, and assessed proliferation of autologous Th cells. Indeed, a significant fraction of Th cells proliferated upon stimulation with CLL-BCR-derived antigen, demonstrating that effector Th cells specific for endogenous CLL antigens are present in CLL patients and that they can support CLL cell activation and expansion.

Interestingly, the patient-derived CLL-specific Th cells had a Th1-like phenotype, characterized by IFN-γ secretion as well as expression of the IFN-γ-associated transcription factor T-bet and the surface markers CXCR3 and CCR5. In contrast, they lacked typical Tfh markers such as CXCR5, ICOS, PD-1, or IL-21 and BCL-6. These findings are in agreement with the observation that IFN-γ levels in CLL patients as well as IFN-γR expression on CLL cells correlated with disease severity [5456]. Even though the exact mechanisms remain to be elucidated, IFN-γ seems to confer resistance to apoptosis and to increase CLL migration. We further demonstrated that IFN-γ secretion was a major mechanism by which CLL-specific Th cells increased CD38 expression on CLL cells [57]. CD38 levels on CLL cells are an indicator of poor prognosis, even though a mechanistic involvement of CD38 in CLL pathogenesis is still debated [58]. Within a patient, proliferating CLL cells are more frequently found in the population that has a higher CD38 expression, and CD38 has been linked to CLL cell migration and survival. In our studies, we found that expression of the IFN-γ-inducible transcription factor T-bet in peripheral blood CLL cells is significantly correlated with CD38 expression [57]. Furthermore, Th cell-derived IFN-γ upregulated CD38 in a mechanism that involved binding of the transcription factor T-bet to two consensus sites in 5′-regulatory regions of intron 1 of the CD38 gene. Thus, it seems that Th cell promote the development of a more aggressive CLL subset through secretion of IFN-γ.

CLL cells seem to express polyreactive and/or autoreactive BCR that provide a certain level of constant signaling [59, 60]. However, sustained BCR signaling can induce anergy and apoptosis. Our studies are in agreement with the view that CLL cells are autoreactive B cells that are rescued from anergy by combined BCR and CD40L activation [5052, 57, 61, 62]. BCR signaling components such as the kinase Syk are promising drug targets in CLL [6365]. Thus, we studied how BCR pathway inhibitors may impact the Th cell help of CLL cells [66]. Interestingly, we found that stimulation by CD40L activated the BCR pathway in CLL cells, including Syk and the downstream components Akt, BLNK, Btk/Itk and pErk1/2. This activation—indicated by blastogenesis and proliferation—was significantly higher in CLL cells compared to normal B cells and could be blocked by Syk inhibition in CLL cells but not in normal B cells.

2.6. Malignant Th cell-B cell interaction: multiple myeloma

Multiple myeloma (MM) is a malignancy characterized by the expansion of plasma cell-derived myeloma cells in the BM. The BM of MM patients and patients with monoclonal gammopathy of undetermined significance (MGUS) display increased numbers of T cells [67], but their role in MM disease development is not fully understood. Primary human MM cells express MHCII molecules as well as the costimulatory molecules CD80 and CD86 and have been shown to be good antigen-presenting cells for Th cells [68, 69]. In addition to the fact that they express high levels of CD40, this suggests that they can participate in cognate interactions with Th cells and benefit from their support. Indeed, CD40 stimulation induced MM cell migration, which is associated with MM disease progression [70]. CD40 stimulation also triggered secretion of IL-6 by myeloma cells, which may mediate MM cell proliferation in an autocrine and/or paracrine mechanism [71]. In addition to CD40L-mediated stimulation, myeloma-specific Th cells can also support MM cells by secreting cytokines [72]. Th17 cytokines such as IL-17 enhanced proliferation of MM cell lines in vitro and in vivo, and supported colony formation of primary human MM cells.

Very recently, we demonstrated that polyclonally activated allogeneic as well as autologous Th cells stimulated blastogenesis and proliferation of MM cells in a CD40L-dependent manner [73]. MM cells increased their cell size, became more granular, reduced their cell surface Ig expression and upregulated the expression of HLA-DR. Proliferation of MM cells was even more pronounced when the Th cell growth factors IL-2 and IL-15 were added. The Th cells from MM patients expressed the chemokine receptors CXCR3 and CCR6 and the transcription factor T-bet as well as low levels of ROR-γt, thus displayed a Th1/17 phenotype. Compared to Th cells from healthy controls, the MM patient-derived Th cells produced lower amounts of IL-4, IL-10, IL-13, and IFN-γ and TNF-α, but higher levels of IL-1β, IL-2, IL-6 and IL-17. Together, our recent study and the previous reports by others suggest that CD40L stimulations is a key mechanism in Th cell-mediated MM cell support, but cytokines such as IL-6 and IL-17 are important components as well.

2.7. Malignant Th cell-B cell interaction: precursor B cell acute lymphoblastic leukemia

The B cell malignancies described in this chapter so far all originate from mature B cells. In contrast, precursor B acute lymphoblastic leukemia (BCP-ALL) derives from B cells of precursor stages during B cell development in the BM. As in most malignancies, the tumor microenvironment plays a key role in BCP-ALL development and progression [12]. Mesenchymal stromal cells, BM endothelial cells, osteoblasts as well as adipocytes have been described to support survival and proliferation of BCP-ALL cells and to confer drug resistance in mechanisms involving both soluble factors and cell membrane-bound molecules.

Memory Th cells generated in the periphery during an immune response migrate to the BM in order to provide long-term memory [7477]. These BM Th cells seem to play a crucial role in normal hematopoiesis [78], but the knowledge about the physiological interactions between BM Th cells and normal precursor B cells is very limited. Both normal precursor B cells and BCP-ALL cells express CD40 [79], MHCII, molecules for adhesion and costimulation [80], receptors for cytokines such as IL-2 and IL-6 [8185] and receptors for BAFF [86, 87]. Thus, they possess all molecules required for cognate interaction with Th cells and therefore seem to be capable of receiving support through the conventional Th cell-B cells interaction pathways. BCP-ALL cells are indeed able to respond to CD40L stimulation with proliferation [88] and with upregulation of the surface molecule CD70 [89]. Furthermore, they upregulate the receptor for IL-3 [90], a cytokine that induces BCP-ALL cell proliferation. Stimulation with CD40L also induces the secretion of chemoattractants [91] and upregulates components of the antigen-processing machinery [92], suggesting that BCP-ALL cells are able to attract Th cells and activate them, thereby inducing a positive feedback loop. Th cell-derived cytokines can act on BCP-ALL cells as well, albeit with diverse effects. IL-2, IL-17 and IL-21, e.g., have been found to stimulate proliferation [83, 93], while IL-4 and IL-13 inhibited BCP-ALL cell growth [88, 9496], and IL-4 as well as TGF-β-induced apoptosis [97, 98]. Cell-cell contact of BCP-ALL cells and activated allogenic Th cells induced activation and maturation of BCP-ALL cells [99]. Further support of an involvement of Th cell in BCP-ALL development comes from the observation that BCP-ALL is associated with certain MHCII haplotypes, suggesting that antigen-presentation to Th cells is involved in the pathogenic mechanisms contributing to BCP-ALL development [100, 101]. In summary, there is evidence that BCP-ALL possess the capacity to exploit microenvironmental Th cells, but whether such leukemia supportive Th cell-BCP-ALL cell interactions actually taking place in patients remains to be determined.

2.8. Concluding remarks

The tumor microenvironment plays a key role in supporting malignant cells. In B cell leukemia and lymphoma, the malignant B cells seem to have retained their ability to receive help from their physiological interaction partners, the Th cells. Consistently, current research supports a contribution of Th cells to the development and progression of various types of B cell malignancies. Effective anticancer therapies should include targeting the cells of the tumor microenvironment. Thus, research efforts leading to the identification and characterization of malignant collaboration between Th cells and malignant B cells may provide novel strategies for therapies aiming to target the tumor microenvironment.


  1. 1. Cooper MD, Alder MN. The evolution of adaptive immune systems. Cell. 2006;124(4):815-822
  2. 2. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986. Journal of Immunology. 2005;175(1):5-14
  3. 3. Liston A, Gray DH. Homeostatic control of regulatory T cell diversity. Nature Reviews Immunology. 2014;14(3):154-165
  4. 4. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. The Journal of Experimental Medicine. 2000;192(11):1553-1562
  5. 5. Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, Barnett B, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science. 2009;325(5943):1006-1010
  6. 6. Bauquet AT, Jin H, Paterson AM, Mitsdoerffer M, Ho IC, Sharpe AH, et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nature Immunology. 2009;10(2):167-175
  7. 7. MacLennan IC. Germinal centers. Annual Review of Immunology. 1994;12:117-139
  8. 8. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102(5):553-563
  9. 9. Papavasiliou FN, Schatz DG. Somatic hypermutation of immunoglobulin genes: Merging mechanisms for genetic diversity. Cell. 2002;109(Suppl):S35-S44
  10. 10. Chaudhuri J, Alt FW. Class-switch recombination: Interplay of transcription, DNA deamination and DNA repair. Nature Reviews Immunology. 2004;4(7):541-552
  11. 11. Sison EA, Brown P. The bone marrow microenvironment and leukemia: Biology and therapeutic targeting. Expert Review of Hematology. 2011;4(3):271-283
  12. 12. Purizaca J, Meza I, Pelayo R. Early lymphoid development and microenvironmental cues in B-cell acute lymphoblastic leukemia. Archives of Medical Research. 2012;43(2):89-101
  13. 13. Ayala F, Dewar R, Kieran M, Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia. 2009;23(12):2233-2241
  14. 14. Shaffer AL, 3rd, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annual Review of Immunology. 2012;30:565-610
  15. 15. Ame-Thomas P, Tarte K. The yin and the yang of follicular lymphoma cell niches: Role of microenvironment heterogeneity and plasticity. Seminars in Cancer Biology. 2014;24:23-32
  16. 16. Ame-Thomas P, Le Priol J, Yssel H, Caron G, Pangault C, Jean R, et al. Characterization of intratumoral follicular helper T cells in follicular lymphoma: Role in the survival of malignant B cells. Leukemia. 2012;26(5):1053-1063
  17. 17. Calvo KR, Dabir B, Kovach A, Devor C, Bandle R, Bond A, et al. IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. Blood. 2008;112(9):3818-3826
  18. 18. Pangault C, Ame-Thomas P, Ruminy P, Rossille D, Caron G, Baia M, et al. Follicular lymphoma cell niche: Identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia. 2010;24(12):2080-2089
  19. 19. Ame-Thomas P, Maby-El Hajjami H, Monvoisin C, Jean R, Monnier D, Caulet-Maugendre S, et al. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: Role of stromal cells in follicular lymphoma pathogenesis. Blood. 2007;109(2):693-702
  20. 20. Johnson PW, Watt SM, Betts DR, Davies D, Jordan S, Norton AJ, et al. Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood. 1993;82(6):1848-1857
  21. 21. Umetsu DT, Esserman L, Donlon TA, DeKruyff RH, Levy R. Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+T cell clones. Journal of Immunology. 1990;144(7):2550-2557
  22. 22. Travert M, Ame-Thomas P, Pangault C, Morizot A, Micheau O, Semana G, et al. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. Journal of Immunology. 2008;181(2):1001-1011
  23. 23. Wahlin BE, Sander B, Christensson B, Ostenstad B, Holte H, Brown PD, et al. Entourage: The immune microenvironment following follicular lymphoma. Blood Cancer Journal. 2012;2(1):e52
  24. 24. Jaffe ES, Pittaluga S. Aggressive B-cell lymphomas: A review of new and old entities in the WHO classification. Hematology/The Education Program of the American Society of Hematology. 2011;2011:506-514
  25. 25. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nature Reviews Cancer. 2004;4(10):757-768
  26. 26. Magrath I. The pathogenesis of Burkitt’s lymphoma. Advances in Cancer Research. 1990;55:133-270
  27. 27. Bornkamm GW. Epstein-Barr virus and the pathogenesis of Burkitt’s lymphoma: More questions than answers. The International Journal of Cancer. 2009;124(8):1745-1755
  28. 28. Sun Q, Burton RL, Lucas KG. Cytokine production and cytolytic mechanism of CD4(+) cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures. Blood. 2002;99(9):3302-3309
  29. 29. Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. The Journal of Experimental Medicine. 2006;203(4):995-1006
  30. 30. Landais E, Saulquin X, Scotet E, Trautmann L, Peyrat MA, Yates JL, et al. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood. 2004;103(4):1408-1416
  31. 31. Khanolkar A, Yagita H, Cannon MJ. Preferential utilization of the perforin/granzyme pathway for lysis of Epstein-Barr virus-transformed lymphoblastoid cells by virus-specific CD4+T cells. Virology. 2001;287(1):79-88
  32. 32. Freeman ML, Burkum CE, Cookenham T, Roberts AD, Lanzer KG, Huston GE, et al. CD4 T cells specific for a latency-associated gamma-herpesvirus epitope are polyfunctional and cytotoxic. Journal of Immunology. 2014;193(12):5827-5834
  33. 33. von Gegerfelt A, Valentin A, Alicea C, Van Rompay KK, Marthas ML, Montefiori DC, et al. Emergence of simian immunodeficiency virus-specific cytotoxic CD4+T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus. Journal of Immunology. 2010;185(6):3348-3358
  34. 34. Fu T, Voo KS, Wang RF. Critical role of EBNA1-specific CD4+T cells in the control of mouse Burkitt lymphoma in vivo. The Journal of Clinical Investigation. 2004;114(4):542-550
  35. 35. Paludan C, Bickham K, Nikiforow S, Tsang ML, Goodman K, Hanekom WA, et al. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt’s lymphoma cells. Journal of Immunology. 2002;169(3):1593-1603
  36. 36. Nikiforow S, Bottomly K, Miller G. CD4+T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. Journal of Virology. 2001;75(8):3740-3752
  37. 37. Fu Z, Cannon MJ. Functional analysis of the CD4(+) T-cell response to Epstein-Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLF1 expression. Journal of Virology. 2000;74(14):6675-6679
  38. 38. Coles RE, Boyle TJ, DiMaio JM, Berend KR, Via DF, Lyerly HK. T cells or active Epstein-Barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice. The Annals of Surgical Oncology. 1994;1(5):405-410
  39. 39. Ma SD, Xu X, Plowshay J, Ranheim EA, Burlingham WJ, Jensen JL, et al. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis. The Journal of Clinical Investigation. 2015;125(1):304-315
  40. 40. Veronese ML, Veronesi A, D’Andrea E, Del Mistro A, Indraccolo S, Mazza MR, et al. Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice. I. T lymphocyte requirement for B cell tumor generation. The Journal of Experimental Medicine. 1992;176(6):1763-1767
  41. 41. Linnerbauer S, Behrends U, Adhikary D, Witter K, Bornkamm GW, Mautner J. Virus and autoantigen-specific CD4+T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders. PLOS Pathogens. 2014;10(5):e1004068
  42. 42. MacArthur GJ, Wilson AD, Birchall MA, Morgan AJ. Primary CD4+T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells. Journal of Virology. 2007;81(9):4766-4775
  43. 43. Guech-Ongey M, Simard EP, Anderson WF, Engels EA, Bhatia K, Devesa SS, et al. AIDS-related Burkitt lymphoma in the United States: What do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood. 2010;116(25):5600-5604
  44. 44. Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, et al. Outcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clinical Cancer Research. 2005;11(4):1467-1473
  45. 45. Muenst S, Hoeller S, Dirnhofer S, Tzankov A. Increased programmed death-1+tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Human Pathology. 2009;40(12):1715-1722
  46. 46. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99(12):4283-4297
  47. 47. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: Cautionary notes and additional considerations and possibilities. Blood. 2011;117(6):1781-1791
  48. 48. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: A target for new treatment strategies. Blood. 2009;114(16):3367-3375
  49. 49. Pizzolo G, Chilosi M, Ambrosetti A, Semenzato G, Fiore-Donati L, Perona G. Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. Blood. 1983;62(6):1289-1296
  50. 50. Ghia P, Strola G, Granziero L, Geuna M, Guida G, Sallusto F, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+T cells by producing CCL22. The European Journal of Immunology. 2002;32(5):1403-1413
  51. 51. Patten PE, Buggins AG, Richards J, Wotherspoon A, Salisbury J, Mufti GJ, et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood. 2008;111(10):5173-5181
  52. 52. Os A, Burgler S, Ribes AP, Funderud A, Wang D, Thompson KM, et al. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Reports. 2013;4(3):566-577
  53. 53. Schjetne KW, Thompson KM, Aarvak T, Fleckenstein B, Sollid LM, Bogen B. A mouse C kappa-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation. International Immunology. 2002;14(12):1423-1430
  54. 54. Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. The Journal of Experimental Medicine. 1993;177(1):213-218
  55. 55. Wilkinson PC, Islam LN. Recombinant IL-4 and IFN-gamma activate locomotor capacity in human B lymphocytes. Immunology. 1989;67(2):237-243
  56. 56. Cordingley FT, Bianchi A, Hoffbrand AV, Reittie JE, Heslop HE, Vyakarnam A, et al. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet. 1988;1(8592):969-971
  57. 57. Burgler S, Gimeno A, Parente-Ribes A, Wang D, Os A, Devereux S, et al. Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-gamma by a T-bet-dependent mechanism. Journal of Immunology. 2015;194(2):827-835
  58. 58. Burgler S. Role of CD38 expression in diagnosis and pathogenesis of chronic lymphocytic leukemia and its potential as therapeutic target. Critical Reviews in Immunology. 2015;35(5):417-432
  59. 59. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118(16):4313-4320
  60. 60. Duhren-von Minden M, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489(7415):309-312
  61. 61. Caligaris-Cappio F. B-chronic lymphocytic leukemia: A malignancy of anti-self B cells. Blood. 1996;87(7):2615-2620
  62. 62. Muzio M, Apollonio B, Scielzo C, Frenquelli M, Vandoni I, Boussiotis V, et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: A molecular signature of anergy. Blood. 2008;112(1):188-195
  63. 63. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578-2585
  64. 64. Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. The Journal of Pharmacology and Experimental Therapeutics. 2013;344(2):378-387
  65. 65. Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015;125(15):2336-2343
  66. 66. Parente-Ribes A, Skanland SS, Burgler S, Os A, Wang D, Bogen B, et al. Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells. Haematologica. 2016;101(2):e59-e62
  67. 67. Perez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martin-Nunez G, Galende J, et al. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire. Cancer. 2006;106(6):1296-1305
  68. 68. Yi Q, Dabadghao S, Osterborg A, Bergenbrant S, Holm G. Myeloma bone marrow plasma cells: Evidence for their capacity as antigen-presenting cells. Blood. 1997;90(5):1960-1967
  69. 69. Walz S, Stickel JS, Kowalewski DJ, Schuster H, Weisel K, Backert L, et al. The antigenic landscape of multiple myeloma: Mass spectrometry (re)defines targets for T-cell-based immunotherapy. Blood. 2015;126(10):1203-1213
  70. 70. Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D, et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood. 2003;101(7):2762-2769
  71. 71. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood. 1995;85(7):1903-1912
  72. 72. Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010;115(26):5385-5392
  73. 73. Wang D, Fløisand Y, Myklebust CV, Bürgler S, Parente-Ribes A, Hofgaard PO, et al. Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice. Leukemia, 2017 Mar 28. doi: 10.1038/leu.2017.69
  74. 74. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. The Journal of Experimental Medicine. 2003;198(11):1753-1757
  75. 75. Herndler-Brandstetter D, Landgraf K, Jenewein B, Tzankov A, Brunauer R, Brunner S, et al. Human bone marrow hosts polyfunctional memory CD4+ and CD8+ T cells with close contact to IL-15-producing cells. Journal of Immunology. 2011;186(12):6965-6971
  76. 76. Tokoyoda K, Zehentmeier S, Hegazy AN, Albrecht I, Grun JR, Lohning M, et al. Professional memory CD4+T lymphocytes preferentially reside and rest in the bone marrow. Immunity. 2009;30(5):721-730
  77. 77. Okhrimenko A, Grun JR, Westendorf K, Fang Z, Reinke S, von Roth P, et al. Human memory T cells from the bone marrow are resting and maintain long-lasting systemic memory. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(25):9229-9234
  78. 78. Monteiro JP, Benjamin A, Costa ES, Barcinski MA, Bonomo A. Normal hematopoiesis is maintained by activated bone marrow CD4+T cells. Blood. 2005;105(4):1484-1491
  79. 79. Law CL, Wormann B, LeBien TW. Analysis of expression and function of CD40 on normal and leukemic human B cell precursors. Leukemia. 1990;4(11):732-738
  80. 80. Mirkowska P, Hofmann A, Sedek L, Slamova L, Mejstrikova E, Szczepanski T, et al. Leukemia surfaceome analysis reveals new disease-associated features. Blood. 2013; 121(25):e149-e159
  81. 81. Wormann B, Anderson JM, Ling ZD, LeBien TW. Structure/function analyses of IL-2 binding proteins on human B cell precursor acute lymphoblastic leukemias. Leukemia. 1987;1(9):660-666
  82. 82. Inoue K, Sugiyama H, Ogawa H, Yamagami T, Azuma T, Oka Y, et al. Expression of the interleukin-6 (IL-6), IL-6 receptor, and gp130 genes in acute leukemia. Blood. 1994;84(8):2672-2680
  83. 83. Touw I, Delwel R, Bolhuis R, van Zanen G, Lowenberg B. Common and pre-B acute lymphoblastic leukemia cells express interleukin 2 receptors, and interleukin 2 stimulates in vitro colony formation. Blood. 1985;66(3):556-561
  84. 84. Kebelmann-Betzing C, Korner G, Badiali L, Buchwald D, Moricke A, Korte A, et al. Characterization of cytokine, growth factor receptor, costimulatory and adhesion molecule expression patterns of bone marrow blasts in relapsed childhood B cell precursor all. Cytokine. 2001;13(1):39-50
  85. 85. Nakase K, Kita K, Miwa H, Nishii K, Shikami M, Tanaka I, et al. Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: Interleukin-2 receptor alpha-chain predicts a poor prognosis. Leukemia. 2007;21(2):326-332
  86. 86. Parameswaran R, Muschen M, Kim YM, Groffen J, Heisterkamp N. A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Research. 2010;70(11):4346-4356
  87. 87. Maia S, Pelletier M, Ding J, Hsu YM, Sallan SE, Rao SP, et al. Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival. PLoS One. 2011;6(6):e20787
  88. 88. Planken EV, Dijkstra NH, Bakkus M, Willemze R, Kluin-Nelemans JC. Proliferation of precursor B-lineage acute lymphoblastic leukaemia by activating the CD40 antigen. The British Journal of Haematology. 1996;95(2):319-326
  89. 89. Troeger A, Glouchkova L, Ackermann B, Escherich G, Hanenberg H, Janka G, et al. Significantly increased CD70 up regulation on TEL-AML positive B cell precursor acute lymphoblastic leukemia cells following CD40 stimulation. Klinische Pädiatrie, 2014; 226(06/07): 332-337
  90. 90. Zhou M, Gu L, Holden J, Yeager AM, Findley HW. CD40 ligand upregulates expression of the IL-3 receptor and stimulates proliferation of B-lineage acute lymphoblastic leukemia cells in the presence of IL-3. Leukemia. 2000;14(3):403-411
  91. 91. Ghia P, Transidico P, Veiga JP, Schaniel C, Sallusto F, Matsushima K, et al. Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. Blood. 2001;98 (3):533-540
  92. 92. Luczynski W, Kowalczuk O, Ilendo E, Stasiak-Barmuta A, Krawczuk-Rybak M. Upregulation of antigen-processing machinery components at mRNA level in acute lymphoblastic leukemia cells after CD40 stimulation. Annals of Hematology. 2007;86(5):339-345
  93. 93. Bi L, Wu J, Ye A, Wu J, Yu K, Zhang S, et al. Increased Th17 cells and IL-17A exist in patients with B cell acute lymphoblastic leukemia and promote proliferation and resistance to daunorubicin through activation of Akt signaling. The Journal of Translational Medicine. 2016;14(1):132
  94. 94. Okabe M, Kuni-eda Y, Sugiwura T, Tanaka M, Miyagishima T, Saiki I, et al. Inhibitory effect of interleukin-4 on the in vitro growth of Ph1-positive acute lymphoblastic leukemia cells. Blood. 1991;78(6):1574-1580
  95. 95. Consolini R, Legitimo A, Cattani M, Simi P, Mattii L, Petrini M, et al. The effect of cytokines, including IL4, IL7, stem cell factor, insulin-like growth factor on childhood acute lymphoblastic leukemia. Leukemia Research. 1997;21(8):753-761
  96. 96. Renard N, Duvert V, Banchereau J, Saeland S. Interleukin-13 inhibits the proliferation of normal and leukemic human B-cell precursors. Blood. 1994;84(7):2253-2260
  97. 97. Manabe A, Coustan-Smith E, Kumagai M, Behm FG, Raimondi SC, Pui CH, et al. Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia. Blood. 1994;83(7):1731-1737
  98. 98. Buske C, Becker D, Feuring-Buske M, Hannig H, Wulf G, Schafer C, et al. TGF-beta inhibits growth and induces apoptosis in leukemic B cell precursors. Leukemia. 1997;11(3):386-392
  99. 99. Renard N, Lafage-Pochitaloff M, Durand I, Duvert V, Coignet L, Banchereau J, et al. Demonstration of functional CD40 in B-lineage acute lymphoblastic leukemia cells in response to T-cell CD40 ligand. Blood. 1996;87(12):5162-5170
  100. 100. Thompson P, Urayama K, Zheng J, Yang P, Ford M, Buffler P, et al. Differences in meiotic recombination rates in childhood acute lymphoblastic leukemia at an MHC class II hotspot close to disease associated haplotypes. PLoS One. 2014;9(6):e100480
  101. 101. Taylor GM, Hussain A, Verhage V, Thompson PD, Fergusson WD, Watkins G, et al. Strong association of the HLA-DP6 supertype with childhood leukaemia is due to a single allele, DPB1*0601. Leukemia. 2009;23(5):863-869

Written By

Simone Bürgler

Submitted: 24 November 2016 Reviewed: 23 March 2017 Published: 12 July 2017